ACE Inhibitor Not Protective Against Heart Damage from Chemotherapy
DAIC
APRIL 9, 2024
The PROACT study reported no impact on cardiotoxicity biomarkers or secondary endpoints related to heart function among patients who took high doses of enalapril, an ACE inhibitor, along with high doses of anthracyclines. The mean dose of enalapril among those who were randomized to take the ACE inhibitor was 17.7mg.
105 
Let's personalize your content